Controlling cholera in the Ouest Department of Haiti using oral vaccines by Kirpich, Alexander et al.
Florida International University
FIU Digital Commons
All Faculty
4-14-2017
Controlling cholera in the Ouest Department of
Haiti using oral vaccines
Alexander Kirpich
University of Florida
Thomas A. Weppelmann
Herbert Wertheim College of Medicine, Florida International University, twepp002@fiu.edu
Yang Yang
University of Florida
John Glenn Morris
University of Florida
Ira M. Longini
University of Florida
Follow this and additional works at: https://digitalcommons.fiu.edu/all_faculty
Part of the Medicine and Health Sciences Commons
This work is brought to you for free and open access by FIU Digital Commons. It has been accepted for inclusion in All Faculty by an authorized
administrator of FIU Digital Commons. For more information, please contact dcc@fiu.edu.
Recommended Citation
Kirpich, Alexander; Weppelmann, Thomas A.; Yang, Yang; Morris, John Glenn; and Longini, Ira M., "Controlling cholera in the Ouest
Department of Haiti using oral vaccines" (2017). All Faculty. 208.
https://digitalcommons.fiu.edu/all_faculty/208
RESEARCH ARTICLE
Controlling cholera in the Ouest Department
of Haiti using oral vaccines
Alexander Kirpich1,2, Thomas A. Weppelmann3, Yang Yang2,4, John Glenn Morris Jr.2,5,
Ira M. Longini Jr.2,4*
1 Department of Molecular Genetics and Microbiology, College of Medicine, University of Florida, Gainesville,
Florida, United States of America, 2 Emerging Pathogens Institute, University of Florida, Gainesville, Florida,
United States of America, 3 Herbert Wertheim College of Medicine, Florida International University, Miami,
Florida, United States of America, 4 Department of Biostatistics, College of Public Health and Health
Professions and College of Medicine, University of Florida, Gainesville, Florida, United States of America,
5 Department of Medicine, College of Medicine, University of Florida, Gainesville, Florida, United States of
America
* ilongini@ufl.edu
Abstract
Following the 2010 cholera outbreak in Haiti, a plan was initiated to provide massive
improvements to the sanitation and drinking water infrastructure in order to eliminate cholera
from the island of Hispaniola by 2023. Six years and a half billion dollars later, there is little
evidence that any substantial improvements have been implemented; with increasing evi-
dence that cholera has become endemic. Thus, it is time to explore strategies to control
cholera in Haiti using oral cholera vaccines (OCVs). The potential effects of mass adminis-
tration of OCVs on cholera transmission were assessed using dynamic compartment mod-
els fit to cholera incidence data from the Ouest Department of Haiti. The results indicated
that interventions using an OCV that was 60% effective could have eliminated cholera trans-
mission by August 2012 if started five weeks after the initial outbreak. A range of analyses
on the ability of OCV interventions started January 1, 2017 to eliminate cholera transmission
by 2023 were performed by considering different combinations of vaccine efficacies, vac-
cine administration rates, and durations of protective immunity. With an average of 50
weeks for the waiting time to vaccination and an average duration of three years for the
vaccine-induced immunity, all campaigns that used an OCV with a vaccine efficacy of at
least 60% successfully eliminated cholera transmission by 2023. The results of this study
suggest that even with a relatively wide range of vaccine efficacies, administration rates,
and durations of protective immunity, future epidemics could be controlled at a relatively low
cost using mass administration of OCVs in Haiti.
Author summary
After the introduction of toxigenic Vibrio cholerae O1 to the Caribbean nation of Haiti in
2010, the country experienced the largest national cholera outbreak in recent history.
With the help of the international community, over $500,000,000 USD was pledged to
finance massive improvements in drinking water and sanitation infrastructure with the
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goal of eliminating cholera transmission by 2023. Over six years later, cholera transmis-
sion continues, with little evidence that any such improvements have been made. In this
study, the use of oral cholera vaccines (OCVs) to reduce the spread of the initial outbreak
and to eliminate future transmission was investigated using a novel mathematical model-
ing framework. Critical parameters including vaccine efficacy, vaccine administration
rates, and duration of protective immunity were evaluated to provide guidelines for the
administration of a National Cholera Vaccine Program in Haiti. Provided the vaccines are
at least 60% effective, all simulations of mass vaccination programs successfully eliminated
cholera by 2023, most within a time frame of only a few years. Not only do the findings
support the use of OCVs to eradicate transmission of cholera in Haiti, they indicate that
OCVs should be mobilized to quash future outbreaks in other countries using active vac-
cine administration campaigns.
Introduction
Since the introduction of toxigenic Vibrio cholerae O1 to Haiti in October 2010, an altered El
Tor biotype has spread throughout the country causing over 750,000 cases and resulted in the
largest national cholera epidemic in recent history [1] [2] [3]. Six years later, cholera transmis-
sion continues, albeit at a diminished rate; with mounting evidence that environmental reser-
voirs of V. cholerae have been established in the warm, tropical surface waters of Haiti [4] [5].
The relatively high proportion (greater than 40%) of the population without access to improved
drinking water sources [6], increased isolation frequency of toxigenic V. cholerae O1 in the
environment [7], and the waning of immunity acquired by those previously infected with El
Tor cholera [8] provide the necessary conditions for seasonal outbreaks in the near future.
In the absence of a complete overhaul of the nation’s drinking water and sanitation infra-
structure, it has been suggested that mass vaccinations by oral inactivated whole-cell cholera
vaccine (OCV) could have completely prevented the ongoing epidemic and be used to mitigate
future transmission of cholera in Haiti [9] [10]. OCVs have demonstrated considerable protec-
tive efficacy (approximately 65%) in rigorously designed clinical trials conducted in India [11]
[12], Bangladesh [13] [14], and Vietnam [15] [16]. Despite their efficacy, any large scale vacci-
nation campaign at the beginning of the Haitian outbreak was not feasible due to the limited
supply of OCVs [17], which at that time were not pre-qualified by the World Health Organiza-
tion (WHO) for the control of cholera outbreaks. Though the WHO acknowledged the avail-
ability of two OCVs that had documented efficacy, feasibility, and cultural acceptance; they
concluded that the relatively short duration of protection from OCVs (roughly 2–5 years),
should not disrupt other health interventions with long-term effects, such as providing appro-
priate medical treatment, implementing interventions to improve drinking water and sanita-
tion, and mobilizing communities to adopt more hygienic practices [18]. Currently, the
position of the WHO is that vaccination should be an effective component of control strategies
in cholera-endemic countries, which they define as countries where culture-confirmed cholera
has been detected in three of the past five years with an incidence of at least 1/1000 population
members in any of those years; both of which now apply to Haiti [19].
With ongoing transmission of cholera six years after the initial outbreak and epidemiologi-
cal characteristic that resemble an endemic rather than epidemic state, the use of OCVs to con-
trol cholera in Haiti warrants further investigation. In the current study, we have used
mathematical models to accomplish three objectives:(i) determine the effect that a reactive vac-
cination campaign would have had on the initial outbreak; (ii) use historical meteorological
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measurements and a recently developed data-driven model to simulate future cholera out-
breaks; (iii) explore the potential benefits of mass immunization programs on simulated future
outbreaks of cholera. These findings may assist in planning future strategic vaccination pro-
grams by providing estimates of critical operational parameters necessary to finally control
cholera transmission in Haiti.
Materials and methods
A dynamic compartment model was used to simulate the impact of multiple vaccine interven-
tion campaigns on cholera transmission in the Ouest Department of Haiti. In this manuscript,
‘elimination of transmission’ and ‘control of cholera’ are used synonymously to mean zero
new human cases, which is not equivalent to the elimination of cholera completely, i.e., the
absence of the causative bacterium from both humans and the environment. This model,
referred to as the intervention model, is an extention of a previously developed framework by
incorporating a vaccinated human compartment to investigate various vaccination interven-
tions that investigate parameters crucial for successful control of cholera using OCVs [20]. In
addition, to make long term epidemic predictions, birth and death rates were included in the
current model to reflect natural population dynamics. The intervention model facilitates the
movement of humans between the susceptible and infected compartments via both short- and
long-cycle transmission. The human-to-human transmission route (short-cycle) represents
the direct contact between humans and the environment-to-human (long-cycle) route repre-
sents transmission via consumption of surface water that serves as an environmental reservoir
of toxigenic V. cholerae O1. The concentration of bacteria in the environmental compartment
is influenced by the influx of toxigenic V. cholerae O1 from the feces of infected humans, bacte-
rial proliferation and survival in response to environmental factors, and bacterial death. After
exposure, infected humans move into either asymptomatic or symptomatic compartments
that correspond to different levels of infectivity and course of illness. The intervention model
diagram is presented in Fig 1.
The following notations for the compartments were used:
• S(t)—the size of the susceptible compartment at a given time t.
• A(t)—the size of the asymptomatic compartment at a given time t.
• I(t)—the size of the symptomatic compartment at a given time t.
• R(t)—the size of the recovered compartment at a given time t.
• V(t)—the size of the vaccinated compartment at a given time t.
• W(t)—bacteria concentration in water at a given time t (environmental compartment).
In this model, the rate of change in the bacterial concentration of the environmental com-
partment is affected by three main processes: an influx of toxigenic V. cholerae O1 from the
feces of infected humans (influenced by precipitation), multiplication of the pathogen in the
environment (influenced by temperature and precipitation), and bacterial death. These pro-
cesses are modeled by functions g(t), h(t), and a time-varying bacterial death rate γW−(t). The
functions g(t) and h(t) have the form:
gðtÞ ¼
rðtÞ
dþ rðtÞ
;
hðtÞ ¼ a exp  
ðrðtÞ   rcÞ
2
2s2
 
þ btðtÞ;
ð1Þ
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where τ(t) is the average ambient temperature and ρ(t) is the total precipitation during week t.
Other notations used in Eq (1) are the threshold parameter δ and calibration parameters α, ρc,
σ, and β.
To reflect the effect of the of the environmental concentration of the bacteria on human
infection we define a function:
f ðtÞ ¼
WðtÞ
kþWðtÞ
; ð2Þ
where κ is the threshold parameter and χ is the cap of the concentration of bacteria in the envi-
ronmental compartment W. Another function m(t) is used together with W(t) to regulate
excessive bacterial growth:
mðtÞ ¼ 1  
WðtÞ
w
¼
w   WðtÞ
w
: ð3Þ
The deterministic model is stated in terms of the ordinary differential equations (ODE). In
the model statement transition rates have notations μ and γ, with corresponding subscripts
indicating the involved compartments of the model and the direction of the flow between
them. Superscripts indicate the nature of the flow between compartments where H represents
human-to-human transmission and W represents environment-to-human transmission. The
birth and death rates of human hosts are denoted by μH+ and μH−. The vaccination rate is con-
trolled by parameter μSV, duration of immunity by μVS, and the vaccine efficacy by parameters
mHVI , m
W
VI, m
H
VA and m
W
VA . The total population size is denoted as N. The intervention model
Fig 1. The complete diagram of the compartment model with vaccination intervention is presented.
The unobserved human compartments and environmental compartment W of the SIRS model are denoted by
circles while the observed data are represented by square boxes. Humans move through the unobserved
SIRS compartments and interact with the unobserved environmental reservoir W which is influenced by the
ambient temperature T and precipitation P. The unobserved number of asymptomatic A and symptomatic I
cholera infections are linked to the observed incidence O. Solid lines denote either the movement of humans
between compartments (thick orange lines) or the bacteria shedding and multiplication in the environment
(thin grey lines). Dashed lines represent the relationships between different elements of the dynamic model
that are incorporated via the system of model equations. Susceptible individuals S move to the vaccinated
compartment V for the duration of immunity provided by the vaccine; where vaccinated individuals can
become infected based on the efficacy of the vaccine.
https://doi.org/10.1371/journal.pntd.0005482.g001
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equations have the form:
dSðtÞ
dt
¼ mHþN þ mRSRðtÞ þ mVSVðtÞ   ðm
W
SA þ m
W
SI ÞSðtÞ
WðtÞ
kþWðtÞ
  ðmHSA þ m
H
SIÞSðtÞðAðtÞ þ IðtÞÞ   ðmSV þ mH  ÞSðtÞ
dVðtÞ
dt
¼ mSVSðtÞ   ðm
W
VA þ m
W
VIÞVðtÞ
WðtÞ
kþWðtÞ
  ðmHVA þ m
H
VIÞVðtÞðAðtÞ þ IðtÞÞ   ðmVS þ mH  ÞVðtÞ
dAðtÞ
dt
¼ mWSASðtÞ þ m
W
VAVðtÞ
  WðtÞ
kþWðtÞ
þ mHSASðtÞ þ m
H
VAVðtÞ
 
ðAðtÞ þ IðtÞÞ   ðmAR þ mH  ÞAðtÞ
dIðtÞ
dt
¼ mWSI SðtÞ þ m
W
VIVðtÞ
  WðtÞ
kþWðtÞ
þ mHSISðtÞ þ m
H
VIVðtÞ
 
ðAðtÞ þ IðtÞÞ   ðmIR þ mH  ÞIðtÞ
dRðtÞ
dt
¼ mARAðtÞ þ mIRIðtÞ   ðmRS þ mH  ÞRðtÞ
dWðtÞ
dt
¼ gðtÞðmAWAðtÞ þ mIWIðtÞÞ þ hðtÞmðtÞWðtÞ   gW  ðtÞWðtÞ
ð4Þ
To avoid identifiability issues, additional assumptions were made regarding the parameters
in model (4). Selected parameters were assigned fixed values based on biological processes
obtained via literature review and estimation from the previous study (please refer to the
S1 Text). Symptomatic and asymptomatic transmission and recovery rates were linked to each
other in a fixed deterministic manner; with mWSA ¼ 3m
W
SI , m
H
SA ¼ 3m
H
SI and μAR = μIR. To ensure
model equilibrium, death and birth rates were assumed to be the same μH+ = μH− and equal to
the annual population birth rate of 22.83 births per 1,000 people [21].
Different levels of vaccine efficacy (VE) were considered [22]. In model (4) vaccine efficacy
is controlled by the parameter ϑ = 1 − VE. For example, ϑ = 0.4 corresponds to a vaccine effi-
cacy of 0.6 or 60% if measured in percentages. In the intervention model, the infection rates
for vaccinated individuals are controlled by parameter ϑ, which has the form mHVA ¼ 3m
H
VI ¼
3WmHSI and m
W
VA ¼ 3m
W
VI ¼ 3Wm
W
SI . Future epidemics in the absence of vaccination were predicted
with VE = 0 (ϑ = 1).
The weekly reported incidence for the Ouest Department of Haiti (including Port-au-
Prince) from October 17, 2010 until April 27, 2014 was used to estimate the effects of tempera-
ture and precipitation on environmental concentrations of toxigenic V. cholerae O1 and chol-
era incidence as described previously [20]. The challenges in the computation of the basic
reproductive number R0 and the effective reproductive number RðtÞ have been discussed in
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detail in previous work [20]. Incidence data were collected by Ministry of Health Haiti (Minis-
tère de la Sante´ Publique et de la Population (MSPP) [23] and compiled by the Pan American
Health Organization (PAHO) [24]. Reported incidence data were adjusted for underreporting
with the assumption that only 75 percent of cases were reported. Daily records of precipitation
(in millimeters) were collected from the Tropical Rainfall Measuring Mission (TRMM) [25]
along with daily temperature readings (in Celsius) collected by the Port-au-Prince airport
monitoring station (IATA: PAP). Environmental data for future dates were extrapolated from
the daily average of the observed readings between October 11, 2010 and June 21, 2014 (Fig A
and B in S1 Text). Please refer to the S1 Text for more details about the extrapolation of future
environmental data.
Simulations for estimation and prediction were performed based on the Markov Chain
assumptions using the set of Eq (4) as infinitesimal generators and the Gillespie algorithm
[26]. Three main simulation scenarios were considered for the study: (1) No intervention was
implemented; (2) A reactive vaccination campaign was implemented five weeks after the initial
2010 outbreak; (3) An OCV intervention campaign was started on January 1, 2017. Since the
third scenario was the most relevant from public health and policy prospective, extensive sensi-
tivity analyses with different vaccination strategies and vaccine efficacy parameters were per-
formed based on this scenario. The population size used for simulation was three million, and
the total number of simulations for each epidemic scenario considered was 500. The starting
points for each epidemic were generated from uniform distributions with the distribution
means corresponding to the number of reported cases during the first week of the observed
epidemic. To cover a reasonable range of vaccination pace and sustainability of vaccine protec-
tion, we considered six possible values of μSV to reach expected waiting times to vaccination of
5, 10, 20, 30, 40 and 50 weeks and three possible values of μV S corresponding to an average of
two, three and five years of protection after vaccination. The exact distributions for waiting
time to vaccination and the duration of protection are given in Tables C and D in the S1 Text.
Details about all the simulation parameter settings and the results of sensitivity analyses are
provided in S1 Text.
Results
Effects of reactive vaccination campaigns during the initial outbreak
The epidemics produced with and without mass vaccination interventions are displayed in
Fig 2. The adjusted reported incidence displayed in orange was compared with the model-
produced symptomatic incidence displayed in dark green. The adjusted reported incidence
was well captured by the the model-produced symptomatic incidence, with a slight overesti-
mation of the number of reported cases after the second year of the epidemic (Fig 2A). As
shown, the total (symptomatic and asymptomatic) number of infections (light green) esti-
mated by the model illustrates that the underlying cholera epidemic in Haiti was actually
much larger than reported. All three million people in the Ouest Department were assumed to
be susceptible to cholera at the onset of the 2010 outbreak. The number of susceptible individ-
uals reached its lowest value, around 75%, by the end of 2011 and then started to grow gradu-
ally to about 80% by the middle of 2014 (Fig 2C). With the addition of the vaccinated
compartment to the estimation model, the effect of a reactive vaccination campaign initiated
five weeks after the beginning of the outbreak using model (4) was investigated. In this cam-
paign, the average time required for a susceptible individual to be vaccinated (referred to here-
after as ‘waiting time’) was 50 weeks, the vaccine efficacy was 60%, and the duration of
protective immunity lasted an average of three years. The exact time periods required to reach
certain levels of vaccine coverage in the population for an average of 50-week waiting time are
Controlling cholera in Haiti using oral vaccines
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displayed in the first row of Table C in the S1 Text. The simulations suggest that the epidemic
could have been completely controlled by August 5, 2012 (95% CI: March 11, 2012; December
16, 2012) had vaccination started after the fifth week of the outbreak (Fig 2B). Even though it
takes some time to reach complete control, the reduction in the number of new cholera cases
becomes visible within a few weeks after the initiation of the vaccination campaign (Fig 2B).
This effect can be attributed to herd immunity in this population, where individuals who have
not been vaccinated have a lower risk of infection due to the reduction in the number of
human hosts available to spread the causative bacterium and a decrease in the environmental
concentrations of toxigenic V. cholerae O1.
Construction of future cholera epidemics for testing OCV interventions
In the absence of effective interventions, the initial outbreak grew in size and spread uncurbed
throughout the entire country in epidemic form. Since the current data-driven dynamic
model (4) estimates the concentration of toxigenic V. cholerae O1 in the environment using
rainfall and temperature measurements, the extrapolation of future climatological data allowed
for the simulation of future seasonal outbreaks in order to test different OCV interventions.
The resulting number of future cholera cases and the punctuation of future epidemics during
the rainy season are shown in Fig 3A. The number of new cases predicted by model (4) for the
short period from May 4, 2014 until March 29, 2015, was in reasonable visual agreement with
the adjusted reported incidence for the same time and created stable, synthetic epidemics
(Fig 3A). Due to the temporary immunity from El Tor cholera infections, the number of sus-
ceptible humans in the Ouest Department eventually stabilizes at around two million people,
leading to an adequate number of hosts to facilitate seasonal cholera epidemics into the distant
future (Fig 3B).
Fig 2. The upper panels show the observed incidence of symptomatic cholera cases adjusted for under-
reporting (orange), the model-fitted incidence of symptomatic cases (dark green), and both symptomatic and
asymptomatic infections (light green) from October 2010 to April 2014, without (A) and with (B) vaccine
intervention initiated on November 17, 2010 (five weeks after the onset of the epidemic). The numbers of
susceptible (purple) and vaccinated (pink) individuals are shown in the lower panels, without (C) and with (D)
vaccine intervention. The average waiting time for a susceptible individual to be vaccinated is 50 weeks, the
vaccine efficacy is 60%, and the average duration of protective immunity is three years.
https://doi.org/10.1371/journal.pntd.0005482.g002
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Effect of proactive vaccination campaigns on future epidemics
Multiple vaccination strategies were explored to verify their ability to control future cholera
epidemics. The first scenario was a mass vaccination campaign set to commence on January 1,
2017, assuming each vaccination, when attempted with the rate μSV, was successful with proba-
bility 1. In this campaign, the average waiting time for an individual to be vaccinated was 50
weeks, vaccine efficacy was set to 60%, and the duration of protective immunity lasted an aver-
age of three years. As shown in Fig 4A, cholera transmission was completely eliminated by
May 20, 2018 (95% CI: January 7, 2018; September 30, 2018). Similar to the reactive vaccine
campaign, this model suggested that the epidemic would be eliminated before all individuals
were vaccinated due to reduction in transmission via herd immunity (Fig 4B). Two additional
vaccination strategies were considered for sensitivity analysis. Both strategies are identical to
the original setting except that 1.) the first additional strategy assumes that the probability of
success for each attempted vaccination was 0.6, resembling non-perfect vaccine delivery due
to any circumstances, and 2.) the second additional strategy delayed the campaign initiation
to September 3, 2017. The reduction in the number of symptomatic cases for all three strate-
gies are presented along with the number of susceptible and vaccinated individuals in Fig C
and Fig D in S1 Text, respectively. The results from all three simulations indicated that even
with lower probability of successful attempts or a later start date, any OCV with a relatively
high efficacy (approximately 60%) could be used to successfully eliminate future cholera
epidemics.
Fig 3. The cholera incidence simulated by the model is presented for the next 10 years without any
intervention, along with the illustration of the number of susceptible population members. In the upper
panel (A) the observed incidence of symptomatic cholera cases adjusted for under-reporting (orange), the
model-fitted incidence of symptomatic cases (dark green), both symptomatic and asymptomatic cases (light
green) are presented. Incidence data from October 2010 to April 2014 were used for estimation, and
incidence data (dark red) from May 2014 until May 2015 were used to illustrate agreement with the model.
The number of susceptible individuals (purple) is displayed in the lower panel (B).
https://doi.org/10.1371/journal.pntd.0005482.g003
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Sensitivity analysis of proactive vaccination campaigns
Sensitivity analyses were performed to evaluate the effects of a wide range of key parameters of
proactive vaccination campaigns including vaccine efficacy (0% to 100%), average waiting
time for an individual to be vaccinated (5 to 50 weeks), and duration of protective immunity
(2, 3 or 5 years). Using these settings, the median times necessary to eliminate cholera trans-
mission in the Ouest Department of Haiti (expressed in weeks from January 1, 2017, the onset
of the campaign) are presented by the duration of protective immunity in Tables E, F and G in
S1 Text and visualized in Fig 5. Additionally, the proportions of failure to eliminate transmis-
sion by 2023 with mass vaccination campaigns among simulated epidemics are provided in
Fig 6. As expected, vaccination campaigns with lower vaccine efficacy or longer average wait-
ing times for individuals to be vaccinated took longer to eliminate cholera transmission
(Fig 5). Interestingly, only campaigns with the lowest levels of vaccine efficacy (30%) and
longest vaccination waiting times (50 weeks) failed to eliminate cholera transmission by
2023. Likewise, the proportion of vaccine campaigns that failed to control cholera transmission
were not significantly different when the vaccine efficacy was 30% or higher regardless of the
waiting time to vaccination, provided the duration of protective immunity from the vaccine
lasts at least three years (Figs 5 and 6). Using the reported vaccine efficacy of OCVs (60%) and
the average duration of protective immunity of at least 3 years, campaigns with a maximum
average waiting time for individuals to be vaccinated of 50 weeks, elimination of transmission
occurred in all of the simulated epidemics with a median time of 22 to 72 weeks (Tables F and
Fig 4. The cholera incidence simulated by the model is presented for the next 10 years with vaccine
intervention, along with the number of susceptible and vaccinated population members. The
intervention was initiated January 1, 2017, assuming a 60% vaccine efficacy, 3 year duration of immunity, and
an average waiting time to be vaccinated of 50 weeks. The upper panel (A) presents the observed incidence
of symptomatic cholera cases (orange and dark red), the model-fitted incidence of symptomatic cases (dark
green), and both symptomatic and asymptomatic cases (light green). The lower panel (B) displays the
numbers of susceptible (purple) and vaccinated (pink) individuals.
https://doi.org/10.1371/journal.pntd.0005482.g004
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G in S1 Text). The corresponding cumulative vaccination coverages at different time points
for this scenario is obtained from the first row of Table C where a 50-week waiting time is
used. For example, 25% of the population has been vaccinated within 14.38 weeks and 50% of
the population has been vaccinated by 34.66 weeks. The coverage at 22 weeks is interpolated to
be about 35%.
Discussion
In agreement with other vaccine intervention models of the great Haitian cholera epidemic
[10] [27], the current study indicated that the use of OCVs in Haiti at the onset of the outbreak
could have greatly reduced the morbidity and mortality from cholera and possibly curtailed
the spread throughout Haiti. At that time, the use of OCVs had yet to be recommended as an
appropriate method for the control of non-endemic cholera [18] and insufficient quantities
were available from the manufacturers, making the implementation of any large-scale vaccina-
tions impossible even if administration was restricted to only high-risk groups [17]. Despite
the planned investment of almost half a billion dollars to improve drinking water and sanita-
tion infrastructure in Haiti between 2013 and 2015 [28], there is little empirical evidence that
Fig 5. The median times to elimination of cholera transmission for parameter settings defined as
combinations of vaccine efficacy (20-100% with 10% increments) and the average waiting time to be
vaccinated (5, 10, 20, 30, 40 and 50 weeks) are presented, stratified by the average duration of immunity after
vaccination of 2 (A), 3 (B), and 5 (C) years. Panel (D) shows slices of the three-dimensional plots at 10, 30,
and 50 weeks for the average waiting time to be vaccinated. Times to elimination exceeding 300 weeks are
truncated at 300 in panels (A)-(C) and not included in panel (D).
https://doi.org/10.1371/journal.pntd.0005482.g005
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any nationally coordinated efforts have been implemented since the earthquake [29]. Addi-
tionally, establishment of such systems would require long-term commitments, ongoing moni-
toring and maintenance, which compared to the relatively rapid protection conferred by
OCVs, makes mass vaccination campaigns an attractive component of any plans for control-
ling cholera in Haiti.
Nevertheless, practical aspects of the implementation of a mass vaccination campaign in
Haiti represent a formidable challenge. From Table C in S1 Text it follows that for an average
waiting time of 30 weeks, 1.5 million people (50% of the population) are expected to be vacci-
nated within 20.79 weeks and 2.25 million people (75% of the population in the Ouest Depart-
ment) within 41.59 weeks. This is also not taking into account that both vaccines currently
provided by the strategic stockpile (Euvichol, Eubiologics Co. and Shancol, Shantha Biotech-
nics) have international protocols that requires two doses given at least two weeks apart [30].
Even though the addition of Euvichol OCV to the stockpile could increase the annual supply
to approximately 10 million doses [31], there are over a billion people living in areas at risk for
cholera [32]. Thus, it is unlikely the entire strategic stockpile would be allocated to a single
country for the purposes of cholera elimination. Indeed, the limited availability of OCVs and
the complex logistics of the administration of multi-dose regimen of vaccine that must be
Fig 6. The proportion of failure to eliminate cholera transmission among all simulated epidemics for
parameter settings defined as combinations of vaccine efficacy (20-100% with 10% increments) and the
average waiting time to be vaccinated (5, 10, 20, 30, 40 and 50 weeks) are presented, stratified by the
average duration of immunity after vaccination of 2 (A), 3 (B), and 5 (C) years. Panel (D) shows slices of the
three-dimensional plots at 10, 30, and 50 weeks for the average waiting time to be vaccinated. Proportions of
failure to eliminate higher than 0.8 are truncated at 0.8 in panels (A)-(C) but are shown in panel (D).
https://doi.org/10.1371/journal.pntd.0005482.g006
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transported and maintained by a cold-chain were some of the main reasons that OCVs were
not utilized during the initial outbreak [33]. However, a single dose of OCV has recently been
demonstrated to be highly effective in the prevention of cholera transmission and the promo-
tion of herd immunity in the population [34]. By targeting campaigns to high-risk populations,
such as rural areas with high rates of surface water consumption that are difficult to reach for
medical intervention [35], the use of fewer vaccines would likely be more effective than the
mass administration of OCV simulated by the current model.
In reality, cholera vaccination pilot programs in Haiti began in early 2012, without the use
of the strategic stockpile. Between April and June 2012, 200,000 doses of Shancol were pur-
chased through funds obtained from the American Red Cross, after which 100,000 doses of
OCV were administered by The Haitian Group for the Study of Kaposi’s Sarcoma and Oppor-
tunistic Infections (GHESKIO) in the urban slums of Port-au-Prince and Zanmi Lasante/Part-
ners in Health (ZL/PIH) in the rural Artibonite Valley. In both demonstration projects, 99.9%
of OCVs were administered successfully, over 90% of participants received both doses of
OCV, an estimated vaccine coverage of 75% in at-risk communities was achieved, and the vac-
cine was well-tolerated with minimal side effects (less than 1%) [36] [37]. Not only was the
OCV determined to be approximately 63% effective [38], the campaign was also associated
with significant improvements in the knowledge of cholera transmission and the practice of
cholera prevention methods in rural population; demonstrating that OCVs can encourage
other cholera control efforts instead of hindering their progress [39]. More recently, the WHO
has responded to the concerns of increased transmission of cholera after hurricane Matthew in
October 2016 by allocating one million doses of Euvichol OCV to Haiti [41], though it has yet
to ascertain the best method of administering these vaccines in the context of a ‘National Chol-
era Vaccination Program (NCVP)’.
Though this study was able to provide valuable insights on the impact that future vaccina-
tion campaigns could have on reducing cholera transmission in Haiti, it is important to men-
tion some basic limitations that arise from the model assumptions. It was assumed that only
susceptible individuals (S) would be vaccinated during the intervention, whereas the immunity
of individuals (S or R) is often unknown and people who acquired immunity from previous
infection would also be vaccinated. This would theoretically lead to the same result, but utilize
more OCVs than necessary due to the redundant vaccination of individuals who acquired
immunity through natural infection. The models assumed homogenous mixing within the
population and equal risk of infection, whereas the differences in population density and
access to improved water and sanitation throughout the Ouest Department are not evenly dis-
tributed. For simplicity, all vaccination strategies assumed that the average vaccine efficacy is
the same for all individuals in the population, which is likely not the case. Similarly, the inclu-
sion of anomalous rainfall events such as hurricanes (ie. Matthew in October 2016) were not
included, hence the use of smoothed precipitation estimates could have affected the size of
future cholera outbreaks and the time to elimination under vaccine interventions. The model
also assumed that no improvements to drinking water and sanitation infrastructure will be
implemented, and that the growth patterns of the lytic phages and toxigenic V. cholerae O1 in
the environment will remain stable. These assumptions, though reasonable, could change in
the future due to the documentation of the shift from Ogawa to Inaba serotype of V. cholerae
O1 identified in the environment and human samples collected from the Ouest Department
[40]. If such a phase-change has happened, then the antibodies formed to one serotype offer
less protection against infections from a different serotype and another large scale epidemic
could follow in the near future. This would provide an even stronger rationale for proactive
vaccination campaigns to commence as soon as possible, as the bi-valent OCV confers protec-
tion from both Ogawa and Inaba serotypes. Lastly, in this study we only considered the Ouest
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Department because of the availability of matched environmental surveillance and incidence
data used to explore the underlying transmission dynamics. It must be understood that, for
national control of cholera using mass administration of OCVs to be successful, campaigns
would have to be initiated in all ten departments to prevent re-introduction after the duration
of protective immunity post-vaccination has waned.
Conclusion
Improvements in drinking water and sanitation infrastructure should remain a priority for
future development due to their long-term effectiveness at preventing cholera and other
water-borne diseases. In the meantime, OVCs could be administered in mass vaccination cam-
paigns or to targeted high risk-groups with or without the use of the strategic stockpile at a rel-
atively low cost (approximately $2 USD/dose). Though the future of the Haitian cholera
epidemic remains uncertain, the results from this study indicate that even with some variabil-
ity in vaccine efficacy and rates of OCV administration, elimination of cholera transmission in
the Ouest Department of Haiti could be possible in a timeframe of only a few years.
Supporting information
S1 Text. Model details. Additional information about the data used, model fitting and out-
puts.
(PDF)
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